BMS and Dr Reddy’s settle Revlimid suit with generics licence
22-09-2020
Gilead to buy Immunomedics for $21bn
14-09-2020
06-10-2020
nitpicker / Shutterstock.com
Bristol Myers Squibb (BMS) has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
BMS, Bristol Myers Squibb, MyoKardia, M&A, mergers and acquisitions, cardiovascular, heart disease, biotech, mavacamten